Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
BioSpace,
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J., Dec.